Novartis Venture Fund
Novartis Venture Fund is a venture capital firm focused on companies that develop novel therapeutics and platforms.
Business Model:
Revenue: $34.4M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Novartis Venture Fund Information
Geographic Data
Address: 355 Main St
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Twitter
Linkedin
Crunchbase
Metrics
9,316,027Website Global Rank
166Website Monthly Traffic
Twitter Followers
Description
Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capital efficiency in the program. We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100&s;000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates. Sectors New therapeutics &a; platforms Medical devices/implants Diagnostics/biomarkers Drug delivery/biopolymers Geography USA/Canada Europe Switzerland Asia/Pacific
Contact Phone:
+16178713536
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2004 | Amphora Discovery | Series C | 20M |
| 3/2020 | Akouos | Series B | 105M |
| 8/2018 | Akouos | Series A | 25.1M |
| 11/2009 | Oxagen | Series C | 0 |
| 11/2013 | Aerpio Pharmaceuticals | Series A | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 9/2018 | Forendo Pharma | Venture Round | 0 |
| 7/2019 | TScan Therapeutics | Series B | - |
| 4/2013 | GenSight Biologics | Series A | 41.7M |
| 8/2008 | Proteostasis Therapeutics | Series A | 45M |
| 5/2006 | Foldrx Pharmaceuticals | Series B | 43M |
| 7/2009 | Symetis | Series B | 0 |
| 4/2014 | Binx Health | Series B | 0 |
| 1/2010 | Cellerix | Series C | 37.7M |
| 11/2009 | Cellerix | Series B | 40.5M |
| 9/2007 | Cellerix | Series B | 37.2M |
| 5/2017 | Vivet Therapeutics | Series A | 41.2M |
| 5/2015 | Realeve | Series D | 38M |
| 9/2020 | Fore Biotherapeutics | Series C | 57M |
| 6/2021 | Ribon Therapeutics | Series C | 0 |
| 10/2021 | Exo Therapeutics | Series B | 0 |
| 4/2007 | MicroCHIPS | Venture Round | 13.4M |
| 3/2011 | Advanced Animal Diagnostics | Series B | 11M |
| 12/2019 | Arctos Medical | Seed Round | 0 |
| 9/2012 | F2G | Equity | 30M |
| 12/2014 | Annexon Biosciences | Series A | 34M |
| 12/2020 | Exo Therapeutics | Series A | 25M |
| 4/2018 | Zikani Therapeutics | Venture Round | 0 |
| 5/2009 | Visiogen | Series D | 40M |
| 9/2019 | Anokion | Series B | 40M |
| 9/2015 | Proteostasis Therapeutics | Series B | 37M |
| 1/2001 | Acorda Therapeutics | Series A | 0 |
| 2/2005 | Covalys Biosciences | Series B | 2.6M |
| 3/2016 | Bionano Genomics | Series D | 9.9M |
| 7/2007 | Ablation Frontiers | Series C | 0 |
| 6/2013 | Akebia Therapeutics | Series C | 0 |
| 9/2012 | FORMA Therapeutics | Series C | 10M |
| 7/2015 | Ra Pharmaceuticals | Series B | 58.5M |
| 6/2016 | F2G | Series E | 60M |
| 11/2004 | Symetis | Series A | 9.6M |
| 8/2020 | GentiBio | Seed Round | 20M |
| 12/2009 | FORMA Therapeutics | Series B | 25.5M |
| 5/2013 | Eledon Pharmaceuticals | Series E | 35.5M |
| 5/2000 | NovImmune | Series A | 14M |
| 9/2021 | Expansion Therapeutics | Series B | 80M |
| 4/2013 | Advanced Animal Diagnostics | Series B | 6M |
| 9/2016 | Rox Medical | Series E | 40M |
| 5/2014 | ImaginAb | Series B | 21M |
| 1/2013 | Aileron Therapeutics | Series D | 12M |
| 12/2006 | Aileron Therapeutics | Series A | 7M |
| 1/2019 | Occlufit | Venture Round | - |
| 2/2015 | Altimmune | Post-IPO Equity | 16M |
| 6/2010 | Foldrx Pharmaceuticals | Venture Round | 29M |
| 7/2010 | Euthymics Bioscience | Series A | 24M |
| 10/2015 | Galera Therapeutics | Series B | 37M |
| 5/2007 | ProCertus BioPharm | Series A | 2.3M |
| 11/2013 | Aileron Therapeutics | Series E | 30M |
| 7/2009 | ProCertus BioPharm | Venture Round | 2.1M |
| 7/2001 | Nereus Pharmaceuticals | Series B | 23.6M |
| 2/2009 | Alios BioPharma | Series A | 8.4M |
| 8/2019 | Renovacor | Series A | 11M |
| 7/2007 | Neovacs | Venture Round | 17.9M |
| 10/2006 | Biofisica | Series A | 5M |
| 6/2009 | Eledon Pharmaceuticals | Series D | 22M |
| 7/2007 | Immune Targeting Systems | Series A | 7.1M |
| 11/2021 | Kedalion Therapeutics | Series B | - |
| 1/2020 | TScan Therapeutics | Series B | 35M |
| 10/2012 | Thesan Pharmaceuticals | Series A | 16M |
| 5/2020 | mPharma | Series C | 0 |
| 12/2009 | Evolva | Post-IPO Equity | 27.5M |
| 4/2011 | Akebia Therapeutics | Series B | 0 |
| 9/2010 | Cylene Pharmaceuticals | Series D | 12M |
| 9/2004 | Nura | Series A | 9.5M |
| 1/2006 | EraGen Biosciences | Series A | 12M |
| 11/2014 | Bionano Genomics | Series C | 0 |
| 2/2019 | Anaveon | Series A | 35M |
| 5/2014 | Sorbent Therapeutics | Series D | 0 |
| 6/2011 | Sorbent Therapeutics | Series B | 0 |
| 7/2009 | Viamet Pharmaceuticals | Series B | 25M |
| 9/2018 | Twentyeight-Seven Therapeutics | Series A | 65M |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 8/2016 | Bionano Genomics | Series D | 31.7M |
| 10/2009 | Evolva | Series B | 27.8M |
| 10/2014 | Viamet Pharma | Series D | 60M |
| 5/2003 | GlycoMimetics | Series A | 4.3M |
| 8/2018 | Artios Pharma | Series B | 0 |
| 7/2009 | Akebia Therapeutics | Series A | 25M |
| 7/2011 | Myopowers Medical Technologies | Series B | 16M |
| 6/2015 | Myopowers Medical Technologies | Series C | 5.1M |
| 3/2005 | TorreyPines Therapeutics | Series C | 0 |
| 2/2012 | Celladon | Venture Round | 43M |
| 10/2005 | Nereus Pharmaceuticals | Series D | 0 |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 6/2007 | BioRelix | Series A | 25.8M |
| 2/2009 | Heptares Therapeutics | Series A | 30M |
| 12/2020 | Faze Medicines | Series A | 81M |
| 6/2015 | Realeve | Series D | 43.2M |
| 6/2023 | Tagworks Pharmaceuticals | Series A | 65M |
| 3/2023 | Oculis | Post-IPO Equity | 0 |
| 11/2003 | Roche Glycart | Series A | 13.6M |
| 6/2023 | Tagworks Pharmaceuticals | Series A | 0 |
| 9/2021 | Flywheel.io | Series C | 0 |
| 5/2001 | AGY | Series B | 13M |
| 5/2002 | Kalypsys | Series A | 42M |
| 2/2022 | Splice Bio | Series A | 0 |
| 8/2006 | Kemia | Series C | 0 |
| 7/2021 | Artios Pharma | Series C | 0 |
| 1/2018 | Oculis | Series B | 20.5M |
| 5/2021 | Oculis | Series C | 0 |
| 7/2015 | GenSight Biologics | Series B | 0 |
| 2/2014 | Aeglea BioTherapeutics | Series A | 0 |
| 7/2019 | Forendo Pharma | Venture Round | 0 |
| 6/2015 | Kanyos Bio | Venture Round | 16.4M |
| 5/2002 | ESBATech | Series A | 0 |
| 2/2006 | EyeSense AG | Series A | 0 |
| 10/2002 | MerLion Pharma | Series A | 0 |
| 1/2010 | Merus | Series B | 0 |
| 3/2007 | Okairos | Series A | 9.6M |
| 11/2006 | Intradigm Corporation | Series A | 16M |
| 6/2005 | Amphora Discovery | Series D | 9.6M |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 5/2001 | Polyphor | Venture Round | 9.3M |
| 2/2008 | Biofisica | Venture Round | 2.4M |
| 2/2007 | Trellis Bioscience | Series B | 10M |
| 4/2014 | Aerpio Pharmaceuticals | Series C | 0 |
| 5/2017 | Lemonaid Health | Series A | 0 |
| 10/2011 | Realeve | Series C | 32M |
| 3/2015 | Zikani Therapeutics | Series A | 22M |
| 11/2021 | LOQUS23 THERAPEUTICS | Seed Round | 0 |
| 6/2007 | Tepha | Series B | 0 |
| 1/2017 | Cavion | Series A | 0 |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 3/2015 | Aeglea BioTherapeutics | Series B | 44M |
| 3/2017 | Aerpio Pharmaceuticals | Venture Round | 0 |
| 8/2021 | GentiBio | Series A | 157M |
| 10/2012 | Neurovance | Venture Round | 7M |
| 4/2014 | Neurovance | Series A | 6.3M |
| 11/2007 | Ascent Therapeutics | Series A | 19M |
| 5/2013 | Effector Therapeutics | Series A | 45M |
| 3/2012 | BioRelix | Venture Round | 2.6M |
| 4/2006 | Sirtris Pharmaceuticals | Series C | 37M |
| 9/2020 | Novellus | Series C | 57M |
| 1/2000 | Viron Therapeutics | Series A | - |
| 9/2009 | PharmAbcine | Series A | 6M |
| 6/2010 | NanoPowers | Series A | 0 |
| 2/2014 | Thesan Pharmaceuticals | Series B | 49M |
| 4/2014 | Alios BioPharma | Series B | 41M |
| 9/2018 | Galera Therapeutics | Series C | 70M |
| 8/2004 | GlycoMimetics | Series A | 5.1M |
| 6/2006 | GlycoMimetics | Series B | 0 |
| 2/2016 | Galera Therapeutics | Series B | 0 |
| 8/2014 | Galera Therapeutics | Series A | 4.7M |
| 7/2017 | NeuroVia | Series A | 14M |
| 3/2007 | Phenomix | Series C | 55M |
| 4/2015 | Nabriva Therapeutics | Series B | 0 |
| 10/2009 | Nabriva Therapeutics | Venture Round | 0 |
| 11/2005 | PTC Therapeutics | Private Equity Round | 26.6M |
| 6/2007 | Aileron Therapeutics | Series B | 7M |
| 6/2009 | Alios BioPharma | Series A | 24M |
| 6/2009 | Opsona | Series B | 4.6M |
| 4/2007 | Protemix | Series A | 14.5M |
| 4/2012 | Advanced Animal Diagnostics | Series B | 4M |
| 7/2009 | Avila Therapeutics | Series B | 30M |
| 5/2009 | NovImmune | Venture Round | 0 |
| 10/2013 | Opsona | Series C | 0 |
| 4/2013 | Opsona | Series C | 0 |
| 9/2016 | Inflazome | Series A | 17M |
| 3/2022 | Epsilogen | Series B | 0 |
| 12/2012 | Bicycle Therapeutics | Venture Round | 6M |
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 10/2020 | Rappta Therapeutics | Series A | 10.6M |
| 10/2014 | Forendo Pharma | Series A | 0 |
| 8/2004 | Evolva | Series A | 14.8M |
| 7/2017 | ESCAPE Bio | Series A | 63M |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 4/2008 | Aileron Therapeutics | Series C | 10.5M |
| 6/2009 | Aileron Therapeutics | Series D | 40M |
| 2/2006 | Catalyst Biosciences | Series B | 30M |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 4/2018 | Enterprise Therapeutics | Series B | 41.3M |
| 8/2020 | ImmPACT Bio | Series A | 0 |
| 12/2018 | Annexon Biosciences | Series C | 75M |
| 8/2012 | Sorbent Therapeutics | Series C | 18.1M |
| 4/2013 | Catalyst Biosciences | Post-IPO Equity | 5.1M |
| 6/2016 | Annexon Biosciences | Series B | 44M |
| 3/2021 | Amphista Therapeutics | Series B | 0 |
| 12/2021 | IKAS Industrial Automation | Series B | 0 |
| 11/2022 | DJEL | Venture Round | 139.4M |
| 1/2015 | Binx Health | Series C | 0 |
| 9/2011 | Eledon Pharmaceuticals | Series D | 23M |
| 10/2014 | Bicycle Therapeutics | Series A | 32M |
| 3/2011 | Euthymics Bioscience | Series A | 4M |
| 6/2002 | Infinity Pharmaceuticals | Series B | 0 |
| 8/2006 | ESBATech | Series B | 41M |
| 10/2009 | Covagen | Seed Round | - |
| 11/2010 | Covagen | Series A | 6.3M |
| 1/2017 | Binx Health | Series D | 0 |
| 10/2004 | Miikana Therapeutics | Series A | 3M |
| 3/2008 | LigoCyte Pharmaceuticals | Series C | 29.5M |
| 1/2021 | TScan Therapeutics | Series C | 100M |
| 12/2009 | FORMA Therapeutics | Series B | 3M |
| 4/2011 | ProCertus BioPharm | Series A | 1.7M |
| 8/2010 | Anchor Therapeutics | Series B | 10M |
| 4/2008 | FORMA Therapeutics | Series A | 4M |
| 1/2016 | Adicet Bio | Series A | 51M |
| 2/2007 | Omeros | Series E | 0 |
| 3/2015 | Galera Therapeutics | Series A | 4.7M |
| 12/2005 | Santhera Pharmaceuticals | Series B | 0 |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 10/2001 | Cylene Pharmaceuticals | Series A | 3.5M |
| 10/2009 | Bicycle Therapeutics | Seed Round | - |
| 10/2014 | Quartet Medicine | Series A | 17M |
| 10/2013 | Merus | Series B | 42.2M |
| 11/2022 | CatalYm | Series C | 0 |
| 12/2013 | Covagen | Series B | 0 |
| 12/2021 | Anaveon | Series B | 0 |
| 9/2019 | Adicet Bio | Series B | 0 |
| 3/2005 | Evolva | Series A | 2.6M |
| 7/2009 | Intellikine | Series B | 51M |
| 8/2008 | ESBATech | Series B | 22M |
| 12/2008 | Catalyst Biosciences | Post-IPO Equity | 40M |
| 11/2021 | Capstan Therapeutics | Seed Round | 63M |
| 3/2010 | Immune Targeting Systems | Series A | 13.2M |
| 6/2006 | NovImmune | Series B | 0 |
| 7/2011 | Binx Health | Series B | 27.1M |
| 3/2012 | ImaginAb | Series A | 12.5M |
| 6/2007 | Cequent Pharmaceuticals | Series A | 9M |
| 8/2004 | AGY Therapeutics | Series C | 9M |
| 5/2014 | Anokion | Series A | 37.5M |
| 6/2017 | Bicycle Therapeutics | Series B | 52M |
| 11/2020 | Catalym | Series B | 59.3M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 12/2006 | Evolva | Series A | 10.3M |
| 12/2008 | Diagnoplex | Series A | 8.3M |
| 10/2014 | Aileron Therapeutics | Series E | 33M |
| 12/2017 | Aelin Therapeutics | Series A | 31.8M |
| 4/2015 | Merus | Series C | 79.1M |
| 8/2011 | Pulmatrix | Series B | 14M |
| 11/2009 | Pulmatrix | Series B | 30.2M |
| 1/2010 | MicroCHIPS | Venture Round | 16.5M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 8/2014 | YourBio Health | Series B | 16M |
| 12/2015 | Effector Therapeutics | Series B | 40M |
| 1/2019 | Ribon Therapeutics | Series B | 65M |
| 4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
| 12/2009 | GlycoMimetics | Series C | 0 |
| 5/2019 | Cala Health | Series C | 0 |
| 12/2012 | Galera Therapeutics | Series A | 11M |
| 3/2022 | Epsilogen | Series B | 0 |
| 2/2022 | Splice Bio | Series A | 0 |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 12/2021 | IKAS Industrial Automation | Series B | 0 |
| 12/2021 | Anaveon | Series B | 0 |
| 11/2021 | LOQUS23 THERAPEUTICS | Seed Round | 0 |
| 11/2021 | Kedalion Therapeutics | Series B | - |
| 10/2021 | Exo Therapeutics | Series B | 0 |
| 9/2021 | Expansion Therapeutics | Series B | 0 |
| 9/2021 | Flywheel.io | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
